aintenance of cellular identity relies on the expression of cell type-specific transcription factors and the underlying state of the epigenome. During somatic cell reprogramming, lineage-committed cells can be converted into iPSCs on expression of critical transcriptional regulators of embryonic stem cells; namely, OCT4, SOX2, KLF4 and MYC (OSKM) 1 . This process results in a complete change in cellular identity, and involves extensive transcriptional and epigenome-wide changes 2 . The state of an epigenome is determined by the activities of chromatin writer, reader and eraser proteins. Therefore, chromatin regulators have emerged as important factors of cell identity and can act as facilitators or barriers to reprogramming . These factors safeguard cellular identity mainly by preventing the activation of pluripotency genes. However, chromatin factors also safeguard cellular identity by perpetuating active somatic-specific gene transcription programs or by preventing the silencing of such genes on OSKM expression. Recent work has indicated that loss of the 'active' histone H3 lysine 27 acetylation (H3K27) mark from the enhancers of somatic-specific genes is an early step in reprogramming 10 . An important remaining question is which chromatin factors counteract the OSKM-mediated silencing of lineage-specific gene expression in reprogramming. We had previously identified DOT1L-mediated histone H3 lysine 79 methylation as one of the key barriers to reprogramming that counteracts the silencing of lineage-specific genes 6 . DOT1L inhibition could also replace KLF4 and MYC in human iPSC generation.
. The state of an epigenome is determined by the activities of chromatin writer, reader and eraser proteins. Therefore, chromatin regulators have emerged as important factors of cell identity and can act as facilitators or barriers to reprogramming 3 . Inhibition of a number of major chromatin-related pathways can facilitate reprogramming, such as DNA methylation 4 , histone deacetylation 5 , histone H3 lysine 9 methylation 6, 7 , CAF-1 complex 8 and NCoR/SMRT corepressors 9 . These factors safeguard cellular identity mainly by preventing the activation of pluripotency genes. However, chromatin factors also safeguard cellular identity by perpetuating active somatic-specific gene transcription programs or by preventing the silencing of such genes on OSKM expression. Recent work has indicated that loss of the 'active' histone H3 lysine 27 acetylation (H3K27) mark from the enhancers of somatic-specific genes is an early step in reprogramming 10 . An important remaining question is which chromatin factors counteract the OSKM-mediated silencing of lineage-specific gene expression in reprogramming. We had previously identified DOT1L-mediated histone H3 lysine 79 methylation as one of the key barriers to reprogramming that counteracts the silencing of lineage-specific genes 6 . DOT1L inhibition could also replace KLF4 and MYC in human iPSC generation.
In subsequent studies, inhibition of DOT1L activity has been shown to increase reprogramming efficiency in a wide range of systems 11, 12 . Importantly, DOT1L inhibitors facilitate the derivation of chemically induced pluripotent stem cells (ciPSCs) from mouse somatic cells 13 . However, the generation of ciPSCs from human cells has not been achieved so far, suggesting that additional barriers exist for human cell reprogramming.
The CBP and EP300 proteins are closely related histone acetyltransferases (HATs) that act as transcriptional coactivators 14 . CBP and EP300 (also known as KAT3A and KAT3B, respectively) are large, multi-domain proteins, which in addition to their catalytic HAT domain, contain bromodomains that bind acetylated histones and are required for chromatin binding [15] [16] [17] . Localization of CBP/ EP300 in the genome has been used to identify cell type-specific enhancers in mice and humans 18, 19 . These coactivators also occupy super-enhancer regions, which have an important role in maintaining cell identity 20, 21 . Both coactivators are required for early embryonic development and proper differentiation of a wide range of cell types 22 . However, the role of these two major coactivators in reprogramming remains largely unknown.
In this study, we carried out a chromatin-focused chemical screen to identify epigenetic regulators that can collaborate with DOT1L inhibition in reprogramming. We discover that CBP/EP300 bromodomain inhibition enhances reprogramming to pluripotency by facilitating the silencing of the somatic gene expression program.
targeting major chromatin-related pathways to uncover those that play a role in maintaining cell identity. The screen was conducted in the presence of a DOT1L inhibitor (iDOT1L-EPZ004777) to identify chromatin pathways that work in parallel with H3K79 methylation, a histone modification we previously identified to be an important regulator of reprogramming 6 (Fig. 1a) . The compound collection consisted of molecules targeting a wide range of chromatin writers, erasers and readers, as well as novel probes developed by the Structural Genomics Consortium and several small molecules previously known to affect reprogramming (Fig. 1a ) 23, 24 . Consistent with previous findings, iDOT1L treatment increased reprogramming approximately three-fold as assessed by the presence of colonies marked by the pluripotency-specific marker Tra-1-60 (Fig. 1b) . Among the top hits from this screen were several known enhancers of reprogramming, such as the GSK3-beta inhibitor CHIR99021 and histone deacetylase inhibitors valproic acid and MS-275, validating our screening approach (Fig. 1b) . In addition to these well-established reprogramming modulators, several bromodomain inhibitors, such as SGC-CBP30, I-CBP112, LP99, GSK2801 and PFI-3, significantly enhanced reprogramming ( Fig. 1b and Supplementary Fig. 1a ).
CBP/EP300 bromodomain inhibitors enhance reprogramming.
We were intrigued to find two structurally distinct chemical probe Kinase (4) Histone demethylase (7) Other (DNMT, HAT, PARP, etc.) (9) Histone deacetylase (12) Histone methyltransferase (13) Bromodomain ( (3 μM) . P values were determined by a two-tailed Student's t-test; *P < 0.05. Bar graphs show the mean and error bars represent standard deviation (n = 3, independent biological replicates). Representative Tra-1-60 stained wells are shown above graph. P values were 0.045, 0.003, 0.048, 0.03 from left to right. e, Phase contrast and GFP fluorescence images of colonies derived by CBP30 treatment showing typical iPSC morphology and silencing of retroviral GFP transgene (scale bar, 100 μm). Representative images are from of one of two independent experiments. f, OCT4, NANOG and SSEA4 immunofluorescence of iPSCs derived by CBP30 treatment. Hoechst 33324 was used to stain the nuclei. Images were taken at ×60 magnification. Representative images are from of one of two independent experiments. g, Hematoxylin and eosin stained sections of teratomas of iPSCs derived from CBP30-treated fibroblasts. Panels show glandular epithelium (endoderm, top), pigmented neural tissue (ectoderm, middle) and cartilage tissue (mesoderm, bottom). Representative images are from of one of three independent teratomas.
compounds targeting EP300 and CBP bromodomains, SGC-CBP30 (referred to as CBP30 (1) and I-CBP112 (2), as potent enhancers of reprogramming. These two compounds are highly specific acetyllysine competitive inhibitors targeting the bromodomains of the coactivators 25, 26 (Fig. 1c) . When used on their own, both compounds increased reprogramming efficiency by 2-3-fold, with CBP30 having a more potent effect at 0.5 μM concentration (Fig. 1d) . The combination of iDOT1L and CBP30 resulted in more than tenfold greater number of Tra-1-60 positive colonies compared with controls. These effects were not dependent on the use of lentiviral vectors as reprogramming with non-integrating episomal plasmids resulted in similar findings ( Supplementary Fig. 1b) . We next evaluated whether the human iPSC lines generated with the use of CBP30 exhibited the canonical hallmarks of pluripotency. Isolated colonies had complete silencing of the exogenous transgenes, as evidenced by the lack of green fluorescent protein (GFP) expression present on the vector backbones (Fig. 1e) . CBP30-derived iPSCs showed robust expression of pluripotency markers OCT4, SOX2, NANOG and stained positively for SSEA4 (Fig. 1f) . When injected into immunodeficient mice, CBP30-derived iPSCs readily formed teratomas containing differentiated cells derived from all three germ layers (Fig. 1g) . Therefore, treatment with CBP30 during reprogramming results in fully pluripotent stem cells.
CBP/EP300 bromodomain inhibitors act early in reprogramming. To understand how CBP/EP300 bromodomain inhibition promotes iPSC generation, we first determined when in the reprogramming process the inhibitors have the maximal effect. We transduced human fibroblasts with OSKM and treated with CBP30 or I-CBP112 for one-week intervals (days 1-6, 7-14, 14-21) or for the two weeks in the beginning (days [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] or at the end of the reprogramming process (days 7-21) (Fig. 2a) . CBP/EP300 bromodomain inhibition was most effective during early time points, significantly increasing iPSC generation when used from days 1-6 and 1-14 ( Fig. 2b and Supplementary Fig. 2a,b) . In contrast, later treatment windows such as days 7-14 or 14-21 had no effect on reprogramming. As the maximal effect was observed by treating the cells on days 1-6 post-OSKM transduction, we conclude that CBP/EP300 bromodomain inhibition can act at early time points in the reprogramming process.
We noticed that iPSC colonies generated by CBP30 alone or in combination with iDOT1L were significantly larger when examined on day 21 (Fig. 2c) . We hypothesized that this could either be due to an earlier emergence of reprogrammed cells or an increase in the cellular proliferation rate after OSKM introduction. To check for the latter possibility, we grew cells in the presence of CBP30, iDOT1L or in combination of these compounds and measured total cell numbers. The compounds alone or in combination had no effect on cellular proliferation of naive or OSKM-transduced fibroblasts ( Supplementary Fig. 2c ). To assess whether compound treatment accelerated the emergence of reprogrammed cells, we then examined the number of Tra-1-60 positive cells by flow cytometry six days after OSKM transduction. At this early time point, CBP30 treatment led to a 3.5-fold increase in the number of Tra-1-60 positive cells, an effect which was additive with iDOT1L ( Fig. 2d and Supplementary Fig. 2d ). These results indicate that CBP/EP300 bromodomain inhibition accelerates the initial stages of reprogramming to generate significantly more reprogrammed cells.
Catalytic inhibition of CBP/EP300 prevents reprogramming. We next asked whether global inhibition of CBP/EP300 catalyzed acetylation would have a similar effect on reprogramming. We employed a recently developed, highly specific HAT inhibitor, A485 (3), to address this question 27 . A485, but not its inactive control (A486 (4)), significantly impaired reprogramming in a dose-dependent manner ( Supplementary Fig. 3a ). We observed a negative effect on cell proliferation at the higher 3 and 10 μM concentrations ( Supplementary  Fig. 3b ). At concentrations where reprogramming was affected (1, 3, and 10 μM), global H3K27 acetylation was severely reduced after five days of treatment with A485 ( Supplementary Fig. 3c ). Recent studies have indicated that bromodomain inhibition can also impact the catalytic activity of P300/CBP and deposition of H3K27Ac on chromatin 28, 29 . To address whether CBP30 or I-CBP112 have an effect on histone acetylation, we treated cells with reprogrammingrelevant concentrations (0.5 μM for CBP30 or 1 μM for I-CBP112) of the compounds and assessed total H3K27Ac and H3K18Ac levels over a time-course ranging from three hours to five days. Both bromodomain inhibitors moderately decreased H3K27 acetylation while having no effect on H3K18Ac levels, an observation consistent with recent findings with an independently developed P300/ CBP bromodomain inhibitor, GNE-049 29 ( Supplementary Fig. 3d ). The effect of A485 on histone acetylation was more extensive, and both H3K18 and H3K27 residues were affected. Importantly, A485 treatment during reprogramming prevented the upregulation of pluripotency-associated genes such as NANOG, LIN28A and LEFTY2 upon OSKM expression, whereas the inactive control compound A486 or CBP30 did not do so (Supplementary Fig. 3e ). These results indicate that although bromodomain inhibition of CBP/EP300 facilitates reprogramming and is associated with a moderate decrease in H3K27 acetylation, extensive inhibition of acetyltransferase activity of the coactivators is incompatible with reprogramming. The latter effect could possibly be explained by the observation that a broad range of proteins involved in transcription, signaling and metabolic regulation are acetylated by these two enzymes 30 , and complete catalytic inhibition probably blocks a number of pathways necessary for reprogramming.
Derivation of two-factor iPSCs with bromodomain inhibition.
As DOT1L inhibition can enable iPSC generation from human fibroblasts in the absence of KLF4 and MYC (ref.
6 ), we next tested whether CBP/EP300 bromodomain inhibitors will also enhance reprogramming in that context. Both I-CBP112 and CBP30 increased reprogramming when treated alone or in combination with iDOT1L in the absence of MYC (Fig. 3a,b and Supplementary  Fig. 4a,b) . CBP30 also enhanced the ability of iDOT1L to derive iPSCs in the absence of both KLF4 and MYC (Fig. 3a) . PCR with vector-specific primers confirmed the absence of KLF4 and MYC transgenes (Fig. 3c) . Two-factor iPSCs generated by CBP30 and iDOT1L treatment were pluripotent, as evidenced by GFP transgene silencing, immunofluorescence and reverse transcription-PCR (RT-PCR) assays for pluripotency markers OCT4, NANOG and SSEA4, and teratoma formation in immunocompromised mice ( Fig. 3c-g ). In addition to replacing two of the transgenes in human somatic cell reprogramming, inhibition of DOT1L boosts the efficiency of chemical reprogramming of mouse cells in the presence of six compounds (valproic acid (V), CHIR99021 (C), 616452 (6), tranylcypromine (T), forskolin (F) and DZNep (Z)-VC6TFZ) 13 . We therefore tested whether a combination of VC6TFZ, iDOT1L and CBP30 could reprogram human fibroblasts. We were unable to generate any human iPSC colonies that could be stably expanded. However, a combination of iDOT1L, forskolin, valproic acid and DZNep could generate robust numbers of iPSCs with OCT4 and SOX2 only ( Supplementary Fig. 4c ). The combination of all four compounds had an additive effect on the efficiency of OS-induced reprogramming. Addition of CBP30 and, to a lesser extent, I-CBP112 resulted in a further increase in reprogramming in the presence of OCT4 and SOX2 ( Fig. 3h and Supplementary Fig. 4d ).
CBP/EP300 bromodomain inhibitors downregulate somaticspecific genes. CBP/EP300 are transcriptional coactivators that are frequently found at enhancers and have a role in the expression of important regulators of cell identity 18, 19 . CBP/EP300 bromodomain inhibition has the largest effect when applied during early stages of reprogramming (Fig. 2b) , a period that is characterized by downregulation of the somatic cell gene expression and the initiation of mesenchymal-to-epithelial transition 31 . We therefore investigated how CBP/EP300 inhibition affects gene expression in fibroblasts before reprogramming by performing a transcriptomic analysis using RNA-sequencing (RNA-seq) in DMSO, CBP30 and A485-treated fibroblasts after five days of treatment. Consistent with the role of CBP/EP300 as coactivators, A485 treatment of fibroblast resulted in extensive transcriptional changes, with most genes being repressed (2,337 downregulated, 1,369 upregulated). In contrast, bromodomain inhibition with CBP30 resulted in a smaller set of genes being affected (333 downregulated versus 61 upregulated genes), a majority of which were also regulated by A485 ( Fig. 4a and Supplementary  Fig. 5a ). Overlap analysis with gene ontology and Hallmark gene sets from the Molecular Signatures Database (MsigDB) indicated that CBP30-downregulated genes were significantly enriched in gene sets such as epithelial-to-mesenchymal (EMT) transition, tissue development and cell differentiation (Fig. 4b) . On the other hand, upregulated genes were not highly enriched in any particular gene set, indicating that the major specific outcome of CBP30 treatment is downregulation of a select group of genes.
We hypothesized that CBP/EP300 bromodomain inhibition leads to a reduction in the transcriptional activity of fibroblast-specific genes. To test this hypothesis, we first constructed a fibroblastrelated gene set (286 genes) on the basis of previously published gene expression profiling of human fibroblasts and their iPSC derivatives ( Supplementary Fig. 5b ). As expected, this gene set was highly enriched for genes present in published gene sets of epithelial-to-mesenchymal transition ( Supplementary Fig. 5c ). Gene-set enrichment analysis (GSEA) revealed that CBP30 treatment of fibroblasts resulted in a highly significant downregulation of the fibroblast-related gene set as well as the Hallmark_EMT gene set, but did not upregulate pluripotency genes on its own ( Fig. 4c and Supplementary Fig. 5d ). The overall average expression values of genes in the fibroblast-related gene set were significantly downregulated with CBP30 and included important developmental regulators and mesenchyme-specific genes, such as PRRX1, GREM1, DKK1, LUM and POSTN ( Fig. 4d and Supplementary Fig. 5e ). Interestingly, a large proportion of fibroblast-related genes were also downregulated by OSKM on day 6 of reprogramming, suggesting that a large proportion of CBP30-regulated genes are destined for repression by OSKM ( Supplementary Fig. 5f ).
We next determined how CBP/EP300 inhibition impacts the transcriptional changes that take place during reprogramming by performing RNA-sequencing of OSKM-transduced fibroblasts treated with the bromodomain inhibitors CBP30 or I-CBP112, or the catalytic inhibitor A485 on day 6 of reprogramming. As expected, OSKM expression in control DMSO-treated cells repressed fibroblast-related genes and induced pluripotency-associated gene sets compared to uninfected control fibroblasts ( Supplementary Fig. 5f ). EP300 and CBP themselves were expressed at comparable levels and were unaffected by CBP30 treatment or OSKM expression ( Supplementary Fig. 5g ). Treatment with either of the bromodomain inhibitors or the catalytic inhibitor further downregulated the fibroblast-related gene set and the overall average expression values of its constituent genes (Fig. 4e,f) . Gene ontology analysis indicated that both bromodomain inhibitors impact similar sets of genes, such as those involved in tissue development, EMT and extracellular structure organization ( Supplementary Fig. 5h ). Interestingly, the expression of pluripotency-related genes was highly induced with CBP30 and I-CBP112 upon OSKM expression, but A485 prevented the upregulation of these genes (Fig. 4e,g ). These data indicate that although bromodomain-mediated interactions of CBP/ EP300 are dispensable for pluripotency gene induction, its full catalytic activity is required.
To determine how CBP/EP300 bromodomain inhibition leads to the downregulation of fibroblast-specific genes, we investigated chromatin-associated changes with CBP30 treatment. We assayed chromatin accessibility by assay for transposase-accessible chromatin (ATAC)-sequencing and determined mono-and tri-methylation of lysine 4 (H3K4me1, H3K4me3) and acetylation of lysine 18 and 27 (H3K18Ac and H3K27Ac) of histone H3 by quantitative ChIP-seq. We observed that the H3K27Ac mark was reduced near transcriptional start sites whereas H3K18Ac was slightly increased (Fig. 5a,b) . In addition, CBP30 treatment resulted in a reduction of H3K27 acetylation over accessible regions in fibroblasts as defined by ATAC-seq peaks, as well as putative enhancer sites marked by H3K4me1 (Fig. 5c,d) . Among the top genes downregulated by CBP30 that also lost H3K27 acetylation was paired-related homeobox protein 1 (PRRX1) encoding a transcription factor strongly associated with mesenchymal cell identity 32, 33 . H3K27 acetylation was reduced in the PRRX1 promoter and the putative upstream enhancer marked by H3K4me1 (Fig. 5e ). In addition, chromatin accessibility of both regions was markedly reduced on OSKM expression and CBP30 treatment (Fig. 5e) . Similar chromatin changes were observed at additional fibroblast-specific genes such as LUM, POSTN and GREM1 (Supplementary Fig. 6 ). Taken together these data suggest that the CBP/EP300 bromodomain is important for maintaining H3K27 acetylation and chromatin accessibility at a set of fibroblast-specific genes.
Suppression of PRRX1 expression by CBP30 is required for efficient reprogramming. We hypothesized that continued expression of the mesenchymal regulator PRRX1 would constitute a barrier to prevent reprogramming. To test this notion, we overexpressed PRRX1 using a constitutive lentiviral backbone and then reprogrammed the resulting fibroblasts with OSKM. PRRX1 overexpression blocked reprogramming to a significant extent and prevented the enhancement observed with CBP/EP300 bromodomain inhibitors CBP30 and I-CBP112 (Fig. 6a,b) . Consistent with a role in the early phase of reprogramming, PRRX1 overexpression inhibited the emergence of Tra-1-60 positive cells on day 6 after OSKM expression (Fig. 6c,d ) and prevented the upregulation of epithelial and pluripotency genes such as E-CADHERIN, NANOG, LIN28A and SALL4 (Fig. 6e) . These results suggest that downregulation of PRRX1 on CBP/EP300 bromodomain inhibition is an important step in transitioning to the pluripotent state. Representative images are from one of two independent experiments. d, RT-PCR for pluripotency markers isolated from iPSCs derived with or without CBP30. Representative images are from one of two independent experiments. e, Phase contrast and GFP fluorescence images of two-factor colonies derived by iDOT1L and CBP30 treatment showing typical iPSC morphology and silencing of retroviral GFP transgene (scale bar, 100 μm). Representative images are from one of two independent experiments. f, OCT4, NANOG and SSEA4 immunofluorescence of two-factor iPSCs derived by iDOT1L and CBP30 treatment. Hoechst 33324 was used to stain the nuclei. Images were taken at ×60 magnification. Representative images of one of two independent experiments. g, Hematoxylin and eosin stained sections of teratomas derived from two-factor CBP30 iPSCs. Panels show glandular epithelium (endoderm) (top), pigmented neural tissue (ectoderm) (middle) and cartilage tissue (mesoderm) (bottom). Images are from one of three independent teratomas. h, Number of Tra-1-60 positive colonies generated by OS-infected fibroblasts treated with iDOT1L (i), valproic acid, forskolin or DZNep in combination with CBP30. Bar graphs show the mean and error bars represent standard deviation. P values were determined by a two-tailed Student's t-test; **P < 0.01, *P < 0.05. n = 3 independent biological experiments with three replicates each. P values were 0.0003 and 0.0253 from left to right. Representative Tra-1-60 stained images of two-factor (OS) reprogramming wells treated with iVF and iVFZ in combination with CBP30 are shown on the right from one of three experiments.
Discussion
In this study, we investigated the effect of a select group of chemical compounds targeting chromatin factors during reprogramming and demonstrated that CBP/EP300 bromodomain inhibition is a potent enhancer of this process. The screen was conducted in the presence of a DOT1L inhibitor and therefore identified chromatin factors that act independently of this important reprogramming barrier 6 . In addition, chemical probes targeting the bromodomains of BRD9 (LP99), BAZ2A/B (GSK2801) and SMARCA4 (PFI-3) proteins enhanced reprogramming, suggesting that bromodomaincontaining chromatin factors may play a broader role in maintaining cell identity. This is also supported by previous work showing that low-dose JQ1 treatment (which is a bromo and extraterminal family protein inhibitor) can also enhance reprogramming 34 . Our screen did not identify JQ1; this may be due to the concentrations of the compound tested, or its effects may be redundant with DOT1L inhibition. In the future, it will be of interest to investigate the mechanisms by which inhibition of these additional bromodomain proteins facilitate reprogramming.
Although CBP and EP300 are well-characterized coactivators, how their bromodomain-mediated interactions help maintain cellular identity has not been studied before. Deletion of EP300 and CBP in mice causes embryonic lethality, and mouse embryonic fibroblasts (MEFs) that lack EP300 display defects in proliferation 35 . DCN  FIBIN  MRGPRF  PLAT  COL16A1  MAP3K7CL  ECM1  GEM  PCOLCE  COL3A1  ELN  MFAP5  C11orf87  C1R  CD248  MFAP4  LUM  CD42EP5  TMEM119  EBF1  RGS4  TSPO  POSTN  ECM2  ACTA2  PEAR1  CCDC80  EMP3  ASPN  MGP  DCN  FIBIN  MRGPRF  MYOCD  COL16A1  ECM1  PCOLCE  COL3A1  ELN  MFAP5  C11orf87  VIT  PRRX1  MFAP4  LUM  RHOJ  TMEM119  EBF1  RGS4  POSTN  HMCN1  ACTA2  PEAR1  PTGS1  FAP  MRVI1  MAP3K7CL  COL12A1  COL5A3  MEGR1  C11orf87  FIBIN  PALMD  IGFBP5  SPOCK1  ANO3  INHBA  MIVI1  MGP  PTGS1  MYOCD  MAP3K7CL  VIT  WFDC1  EBF1  GEM  MAFP5  HMCN1  SERPINB2  ACTA2  PLAT  B3GALT2  CSPG4  SPOCD1  NTN4  NOV  ANGPT1  COL16A1   KIAA1551  NANOG  LIN28B  VAMP8  NAP1L3  CDH1  CXDAR  FAM169A  ADD2  BCL11A  TDRP  AASS  TRIM71  L1TD1  KDR  STRBP  RAB39B  CTSV  NPTX2  FOS  NRARP  RBPMS2  SEMA6A  CACNA2D2  EPCAM  TPD52  SALL2  HERC5  ARID3B  PLS1  VASH2  ZNF165  KDR  PALD1  TPD52  LIN28A  SALL2  ZDHHC23  LSR  CACNA2D2  GYG2  EGLN3  GCA  MARVELD3  HERC5  ZFP42  NPTX2  FOS  SNX10  KIF5C  USP44  NANOG  CDH1  CTSV  CPVL  SLAIN1  FXYD6  F11R  IGDCC3  PAIP2B  GLDC  RRAGD  SFRP2  PRSS8  KCNK5  IQGAP2  GDF3  KCNS3  CNTNAP2  CLDN10  CYP4X1  LCK  STOX2  CALB1  CYYR1  PTPZR1  CACNA2D2  TNNI3  KCND2  VASH2  FZD5  GARBB3  LINGO1  UNC5D  CA2  SYT6  DPPA2  LEFTY1  ADD2 . P values were calculated by hypergeometric distribution. Number of genes (n) in comparison were 316. c, GSEA analysis of CBP30-induced changes in uninfected fibroblasts with respect to fibroblast-related gene set (top) and pluripotency-related gene set (bottom). RNA-sequencing was carried out on three biologically independent samples. P values for the significance of enrichment scores were calculated by permuting the gene sets (1,000 permutations) and false discovery rate (q val) was used as an adjustment for multiple hypothesis testing. d, log 2 fold change in the expression levels of the indicated genes by CBP30 treatment compared with DMSO treatment. e, GSEA analysis of gene expression changes induced by CBP30, I-CBP112 or A485 treatment 6 days after OSKM expression with respect to fibroblast-related gene set (top) and pluripotencyrelated gene set (bottom). P values for the significance of enrichment scores were calculated by permuting the gene sets (1,000 permutations) and false discovery rate (q val) was used as an adjustment for multiple hypothesis testing. Heatmaps show the relative expression of the top 30 genes in each gene set. NES, normalized enrichment score. f, Average expression levels of the 286 genes in the fibroblast-related gene set in OSKM-transduced fibroblasts on treatment with the indicated compounds on day 6 of reprogramming. Whiskers indicate 95% confidence interval. P values were calculated by a twosided Wilcoxon signed-rank test. g, Average expression levels of the 246 genes in the pluripotency-related gene set in OSKM-transduced fibroblasts on treatment with the indicated compounds on day 6 of reprogramming. Whiskers indicate 95% confidence interval. P values were calculated by a two-sided Wilcoxon signed-rank test.
In mouse embryonic stem cells (ESCs), EP300 knockout does not affect the self-renewal capacity but results in abnormal expression of somatic germ layer-specific genes on differentiation 36 . Combined knockdown of EP300 and CBP compromises pluripotency, indicating that these two coactivators have redundant roles in maintaining stem cell identity 37 . Because of the structural similarity between the bromodomains of EP300 and CBP, the inhibitors we employed during reprogramming do not distinguish between these two coactivators 25, 26 . We were therefore unable to evaluate the contribution of each individual coactivator in the reprogramming phenotype. Based on messenger RNA expression levels, both are expressed at comparable levels and their expression levels do not significantly change with OSKM expression. Interestingly, complete inhibition of their HAT activity using A485 abrogated reprogramming and prevented the activation of pluripotency genes. Given the multitude of protein targets of these two acetyltransferases 30 , it is likely that HAT inhibition has very broad effects in cells that are undergoing reprogramming. In contrast, blocking bromodomain-mediated interactions of EP300 and CBP appears to facilitate reprogramming through a locus-specific effect on the transcriptional profile of somatic cells.
During reprogramming, exogenous factors impose on the somatic cell a drastically different transcriptional state. To achieve this new state, reprogramming must overcome the mechanisms that somatic cells have in place to preserve cell identity. Incomplete repression of starting cell transcriptional networks results in aberrant cell fate changes in many transcription factor-induced lineage conversions 38 . In the case of fibroblasts, one of the first steps in reprogramming to pluripotency is the downregulation of mesenchyme-specific genes 31 . Concomitantly, somatic-specific enhancers, marked by active histone H3K27 acetylation, get silenced 10, 39 . This is accompanied by loss of H3K27 acetylation and eviction of EP300 from these genomic regions. CBP/EP300 also occupy super-enhancer regions which have an important role in maintaining cell identity 20 . Disruption of super-enhancers and high density EP300 enhancers can shape responses to stimuli-induced transcriptional changes and cell fate decisions 21 . CBP/EP300 bromodomain inhibitors have been shown to suppress physiological transcriptional responses and malignancy-associated gene networks in a cell type-specific manner 40, 41 . Similarly, inhibition of RNA polymerase II factor RPAP1, which is involved in RNA pol II's interaction with the Mediator complex has recently been shown to facilitate reprogramming, in part by leading to a decrease in the expression of regulators of cell identity and development 42 . Despite repeated attempts, we were not able to directly examine CBP/EP300 occupancy during reprogramming due to lack of suitable antibodies. However, our ATAC-seq and ChIP-seq data indicate that CBP/EP300 bromodomain inhibition facilitate reprogramming by decreasing the transcriptional activity of somatic-specific genes. This is accompanied by a decrease in promoter-and enhancer-associated H3K27 acetylation. This finding is consistent with recent data on the chromatin-associated effects of an independently developed CBP/EP300 bromodomain inhibitor 29 . Bromodomain inhibition has also recently been shown to block the formation of active EP300 biomolecular condensates 43 . Interestingly, the addition of bromodomain inhibitors during reprogramming does not prevent the induction of pluripotency genes on OSKM expression. This observation suggests that CBP/ EP300 can be recruited to pluripotency-associated genes independent of their bromodomain-mediated interactions. It is possible that whereas maintenance of pre-existing active enhancers is in part dependent on CBP/EP300 bromodomains, CBP/EP300 can be recruited to newly activated enhancers via their direct interactions with exogenously expressed master transcription factors [44] [45] [46] . Our results point to distinct and context-dependent functions for different coactivator domains in somatic cell reprogramming.
Gene expression analyses indicated that there is widespread downregulation of fibroblast-specific genes with CBP/EP300 bromodomain inhibition. We identified the mesenchyme-specific transcription factor PRRX1 as an important downstream target of CBP/EP300. Interestingly, PRRX1 is predicted to be a master transcription factor for human dermal fibroblasts on the basis of its association with a highly H3K27 acetylated super-enhancer region 20 . PRRX1 is also an important regulator of mesenchymal cells, EMT, and has been linked to increased transforming growth factor-β signaling [47] [48] [49] . Although not previously identified as a barrier in human somatic cell reprogramming, PRRX1 seems to act similarly to other somatic-specific master transcription factors, such as ZEB1, TWIST1 and FRA1, which inhibit reprogramming 6, 10 . Inability to repress PRRX1 results in reduced epithelial and pluripotency gene activation. Whether PRRX1 acts as a direct repressor of such genes during reprogramming remains to be investigated. Taken together, our findings point to a model in which CBP/EP300 bromodomainmediated interactions serve to maintain a somatic cell-specific transcriptional program and thereby antagonize OSKM-mediated reprogramming (Fig. 6f) .
In conclusion, our results indicate that CBP/EP300 bromodomain-mediated interactions are important in safeguarding cellular identity. Therefore, inhibitors targeting these interactions, such as those identified in this study, may be used in improving various direct lineage conversions, as well as in developing protocols for the derivation of chemically induced iPSCs from human somatic cells.
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Methods
Chemical screen. Two thousand cells were seeded onto 96-well plates and were infected next day with lentiviral OSKM vectors (Addgene, catalog no. 21162, 21164). DMSO and compounds were added at 1:1,000 dilution in triplicate. Final concentrations of the compounds are given in Supplementary Table 1 . iDOT1L (EPZ004777, Tocris) was used at 3 μM. Medium was changed every other day with fresh compound addition. On day 6, cells were trypsinized and transferred onto MEF-coated 24-well plates. The next day medium was switched to hESC medium (20% KOSR, 1% l-glutamine, 1% non-essential amino acids, 0.055 mM betamercaptoethanol, 10 ng ml −1 bFGF in DMEM/F12). Plates were fixed and stained for Tra-1-60 on day 21.
Reprogramming assays. Human fibroblast cells (dH1f) were a gift of G.Q. Daley (Harvard Medical School). Cells were grown as described 50 and seeded in fibroblast medium (DMEM (Life Technologies), 10% fetal bovine serum) at a density of 50,000 cells per well of a 12-well plate and transduced overnight with OSKM viruses (Addgene, plasmids no. 21162 and no. 21164). Compounds were added the next day and replenished every two days. On day 7 after OSKM transduction, fibroblasts were passaged onto mitomycin-C-treated MEFs. Medium was changed to hESC medium the next day. To quantify the number of iPSC colonies, Tra-1-60 antibody staining was performed on day 18-21 after OSKM transduction. CBP30 and I-CBP-112 were gifts of the Structural Genomics Consortium. Additional compounds used in the chemical reprogramming experiments were obtained through the Structural Genomics Consortium (https://www.thesgc.org/chemicalprobes). For reprogramming with episomal plasmids, the following vectors were used: pCXLE-hOCT3/4-shp53-F, Addgene plasmid no. 27077; pCXLEhUL, Addgene plasmid no. 27080; pCXLE-hSK, Addgene plasmid no. 27078. Each plasmid (1 μg) was electroporated into 1 × 10 6 million fibroblasts using a 4D-Nucleofector system (Lonza). Fibroblasts were cultured in DMEM medium for seven days after which they were passaged onto mitotically arrested MEFs and cultured in hESC medium. For two-factor reprogramming, 50,000 dH1f cells were infected with pMIG-OCT4 (Addgene plasmid no. 17225) and pMIG-SOX2 (Addgene plasmid no. 17226) viruses at a multiplicity of infection of 5.
Cell proliferation assay. Two thousand cells were seeded onto 96-well plates. On the following day, cells were either infected with lentiviral OSKM vectors or left uninfected. The uninfected group was treated with compounds on the same day and the OSKM-transduced group was treated with compounds the day after. Cell proliferation was measured with the CellTiter-Glo Luminescent Cell Viability Assay (Promega) according to manufacturer's instructions using luminometric measurements with a plate reader (Synergy H1 Reader, BioTek).
Vectors and virus production. 293T cells were plated at a density of 2.5 × 10 6 cells per 10-cm dish. The next day, cells were transfected with 2.5 µg viral vector, 2.25 µg psPAX2 (Addgene plasmid no. 12260) for lentivirus and pUMVC (Addgene plasmid no. 8449) for retroviruses and 0.25 µg pCMV-VSV-G (Addgene plasmid no. 8454) using 20 µl FuGENE 6 (Promega) in 400 µl DMEM per plate. Supernatants were collected 48 h and 72 h post-transfection and filtered through 45-µm pore size filters. To concentrate the viruses, viral supernatants were mixed with PEG3350 solution (Sigma P3640, dissolved in PBS, 10% final concentration) and left overnight at 4 °C. The next day, supernatants were centrifuged at 2,500 r.p.m. for 20 min, and the pellets were re-suspended in PBS. Viral transductions were carried out overnight in the presence of 8 µg ml −1 protamine sulfate (Sigma). GFP-expressing viruses were titered on 293T cells. PRRX1 expression vector in pLenti6.2/V5-DEST was obtained from DNASU Plasmid Repository (Clone ID: HsCD00330006) 51 . Transduced cells were selected with 7 μg ml −1 blasticidin.
Immunostaining. To quantify the number of iPSC colonies, immunostaining of reprogramming plates was performed as described 6 . Briefly, cells were fixed with 4% paraformaldehyde and incubated with biotin-anti-Tra-1-60 (eBioscience, catalog no. 13-8863-82, 1:250) and streptavidin horseradish peroxidase (Biolegend, catalog no. 405210, 1:500) diluted in PBS (3%), FCS (0.3%) Triton X-100. Staining was developed with the DAB peroxidase substrate solution (0.05% 3,3'-diaminobenzidine, Sigma D8001, 0.05% nickel ammonium sulfate and 0.015% H 2 O 2 in PBS, pH 7.2) and iPSC colonies were quantified with ImageJ software (https://imagej.nih.gov/ij/). For the characterization of iPSC lines, colonies were passaged onto coverslips coated with Matrigel in mTeSR medium (Stemcell Technologies). The cells were fixed for 20 min with 4% paraformaldehyde in PBS, washed several times and incubated overnight at 4 °C with primary antibody diluted in 3% donkey serum, 3% BSA, 0.01% Triton X-100 in PBS. Antibodies used were SSEA4/A647 (BD, catalog no. 560219), NANOG (Abcam, catalog no. ab21624), OCT4, (Abcam, catalog no. ab19857). For NANOG and OCT4, Alexa-488-conjugated secondary antibodies (Molecular Probes) were used. Nuclei were stained with Hoechst 33342 (ThermoFisher, catalog no. H3570). Images were acquired using a Nikon 90i confocal microscope.
Flow cytometry. Cell surface Tra-1-60 expression was analyzed with an Accuri C6 flow cytometer (BD) using PE-conjugated anti-human TRA-1-60-R antibody (Biolegend, catalog no. 330610).
Teratoma assays. All experiments were carried out under a protocol approved by Koç University Animal Experiments Ethics Committee and all relevant ethical regulations were complied with. Teratoma injections were performed as previously described 52 . Briefly, iPSCs from a confluent 6-well dish were collected using collagenase IV (1 mg ml −1 in DMEM/F12) and re-suspended in 100 μl ice-cold 1:1 mixture of Matrigel (Corning) and DMEM. Intramuscular injections were performed in severe combined immunodeficiency mice. Teratomas were collected 8-12 weeks after injection and analyzed histologically.
Quantitative RT-PCR analyses. Total RNA was extracted using NucleoSpin RNA kit (Macherey Nagel) and reverse transcribed with Hexanucleotide Mix (Roche). The resulting complementary DNAs were used for PCR using SYBR-Green Master PCR mix (Roche) and run on a LightCycler 480 Instrument II (Roche) with 40 cycles of 30 s at 95 °C, 30 s at 60 °C and 30 s at 72 °C. All quantifications were normalized to an endogenous β-actin control. The relative quantification value for each target gene compared to the calibrator for that target is expressed as 2
(Ct and Cc are the mean threshold cycle differences after normalizing to β-actin). List of primers are in Supplementary Table 2 .
RNA-sequencing. Control or OSKM-transduced fibroblasts were treated for 6 days with DMSO, CBP30 (0.5 μM), I-CBP112 (1 μM) or A485 (1 μM). Total RNA was prepared using Direct-zol kit according to manufacturer's instructions (Zymo Research). Libraries were prepared using NEBNext Poly(A) mRNA Magnetic Isolation Module from the NEBNext ultra-directional RNA kit (with actinomycin) to create a first stranded library. Genes were considered to be differentially regulated based on log 2 fold change > 0.5 and P < 0.05. Differential gene expressions between pluripotent stem cells and fibroblast cells were computed by affy and limma packages from R. Samples of dH1f and BJ fibroblasts are compared to their respective iPSCs and embryonic stem cells from GEO data series GSE55679. Genes that have a log 2 fold change value of 3 or more in all fibroblasts compared with pluripotent cells were categorized as the fibroblast-related gene set. Rank-ordered gene lists were used for gene-set enrichment analysis 53 .
ChIP-sequencing. Per chromatin immunoprecipitation experiment, 5 × 10 6 dH1f cells were used. ChIP-seq assays were performed in triplicate as described previously at the same time points as RNA-seq experiments 23 . Briefly, for quantitative ChIP experiments, 4 × 10 6 SF9 cells were spiked into the pool at 1:5 ratio. The cells were then cross-linked by formaldehyde treatment, and chromatin was fragmented to 200-300 base pairs (bp) by sonication using a Biorupter Pico (Diagenode). Each lysate was immunoprecipitated with 5 μg of primary antibody. Purified DNA was used for library preparation using a NEBNext Ultra DNA sample preparation kit (NEB) according to the manufacturer's recommendations. The samples were multiplexed, quantified on Tapestation (Agilent), and sequenced on a NextSeq 500 (Illumina) platform (paired-end, 2 × 41 bp). Sequencing depth was in excess of 20 million reads per sample, suggesting sufficient coverage. Antibodies for the ChIP-seq experiments were: anti-H3K27Ac (Active Motif, 39133), anti-H3K18Ac (Abcam, ab1191), anti-H3K4me3 (Merck Millipore, 07-473), anti-H3K4me1 (Diagenode, C15410194).
ATAC-seq. ATAC-seq was performed using 100,000 cells for the transposition reaction, which was performed as described by Buenrostro et al. using in-houseproduced transposase 54 . Subsequently, the samples were purified using the GeneJET PCR purification kit (Thermo). PCR amplification was performed using the following protocol: 3 min at 72 °C, 30 s at 98 °C and 11 cycles of 10 s at 98 °C, 30 s at 63 °C, and 3 min at 72 °C. The samples were then purified using the GeneJET PCR purification kit and eluted with 20 μl of TE buffer. Samples were then validated on a Tapestation (Agilent) to determine library size and quantification before paired-end (2 × 41 bp) sequencing on a NextSeq 500 (Illumina) platform.
Processing of ChIP-seq and ATAC-seq data. A computational pipeline was written calling scripts from the CGAT toolkit to analyze the next-generation sequencing data (https://github.com/CGATOxford/CGATPipelines) 55 . Bowtie software v.0.12.5 was used to align the reads to the human hg19 reference genome 56 . Reads were only considered that were uniquely aligned to the genome with up to two mismatches. For quantitative ChIP, the number of reads mapping to SF9 cells was determined for each sample. Bedtools v.2.2.24 was used to generate bedgraph files from the mapped BAM files using the scaling factor derived from the SF9 read count. Averaged tracks for each condition were produced representing the mean of the scaled values for biological replicates. Homer tag directories were then produced using the raw read function, and coverage plots around the transcription start sites were plotted in R. MACS software (v.1.4.2) was used to identify enrichment of intervals of H3K27Ac following ChIP-seq and regions of open chromatin following ATAC-seq. Sequencing of the whole cell extract was performed to determine the background model when analyzing ChIP-seq. For ATAC-seq, peak callers were run without a background. For visualization as a University of California Santa Cruz Genome Browser track, the bam files generated from Bowtie were converted to BigWig files.
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
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Data analysis
Custom computational analysis code can be found on github https://github.com/cgat-developers/cgat-flow and https://github.com/ Acribbs/cribbslab/tree/master/Pipelines. For ChIP and ATAC-Seq experiments Bowtie software v0.12.5 was used to align the reads to the human hg19 reference genome. Bedtools version 2.2.24 was used to generate bedgraph files from the mapped BAM files.Homer tag directories were then produced using the raw read function, and coverage plots around the TSS were plotted in R. MACS software (v1.4.2) was used to identify enrichment.
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Next-generation sequencing data that support the findings of this study have been deposited in Gene expression omnibus (GEO) with the primary accession code GSE118220.
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Blinding
The investigators were not blinded to group allocation during data collection and/ or analysis. There is no need of blinding because most of experiments have been done by 3 researchers independently. The ChIP-seq, RNA-seq, ATAC-Seq results can cover whole genome or transcriptome and do not cause any bias.
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Authentication
Gene expression by RT-qPCR of dH1f and iPSCs were used to confirm the expression of specific somatic or pluripotency genes. No other cell line authentication was performed.
Mycoplasma contamination
All cells were tested for mycoplasma bi-monthly and were negative.
Commonly misidentified lines
(See ICLAC register)
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